NO863539L - Fremgangsmaate for isolering av (+)-6-klor-5,10-dihydro-5-((1-metyl-4-piperidinyl)acetyl) -11h-dibenzo (b,e) (1,4) diazepin-11-on. - Google Patents
Fremgangsmaate for isolering av (+)-6-klor-5,10-dihydro-5-((1-metyl-4-piperidinyl)acetyl) -11h-dibenzo (b,e) (1,4) diazepin-11-on.Info
- Publication number
- NO863539L NO863539L NO863539A NO863539A NO863539L NO 863539 L NO863539 L NO 863539L NO 863539 A NO863539 A NO 863539A NO 863539 A NO863539 A NO 863539A NO 863539 L NO863539 L NO 863539L
- Authority
- NO
- Norway
- Prior art keywords
- dibenzo
- dihydro
- acetyl
- chloro
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- UFJWXHOFKIGIAF-UHFFFAOYSA-N 1-chloro-11-[2-(1-methylpiperidin-4-yl)acetyl]-5h-benzo[b][1,4]benzodiazepin-6-one Chemical compound C1CN(C)CCC1CC(=O)N1C2=C(Cl)C=CC=C2NC(=O)C2=CC=CC=C21 UFJWXHOFKIGIAF-UHFFFAOYSA-N 0.000 title description 4
- 238000009413 insulation Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 6
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims 2
- -1 1-methyl-4-piperidinyl Chemical group 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 239000001358 L(+)-tartaric acid Substances 0.000 description 3
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- KUPPZIQYLWKDKQ-UHFFFAOYSA-N 1-(1-chloro-5,6-dihydrobenzo[b][1,4]benzodiazepin-11-yl)-2-(1-methylpiperidin-4-yl)ethanone Chemical compound ClC1=CC=CC=2NCC3=C(N(C=21)C(CC1CCN(CC1)C)=O)C=CC=C3 KUPPZIQYLWKDKQ-UHFFFAOYSA-N 0.000 description 1
- UIKHKLFBHLPAPO-UHFFFAOYSA-N 2,3-diacetyl-2,3-dihydroxybutanedioic acid Chemical compound CC(=O)C(O)(C(O)=O)C(O)(C(C)=O)C(O)=O UIKHKLFBHLPAPO-UHFFFAOYSA-N 0.000 description 1
- GBJFSZCDZHSAOP-UHFFFAOYSA-N 2,3-dihydroxy-4-methoxy-4-oxobutanoic acid Chemical compound COC(=O)C(O)C(O)C(O)=O GBJFSZCDZHSAOP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000026 anti-ulcerogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000008533 dibenzodiazepines Chemical class 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853531682 DE3531682A1 (de) | 1985-09-05 | 1985-09-05 | (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO863539D0 NO863539D0 (no) | 1986-09-04 |
| NO863539L true NO863539L (no) | 1987-03-06 |
Family
ID=6280185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO863539A NO863539L (no) | 1985-09-05 | 1986-09-04 | Fremgangsmaate for isolering av (+)-6-klor-5,10-dihydro-5-((1-metyl-4-piperidinyl)acetyl) -11h-dibenzo (b,e) (1,4) diazepin-11-on. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4668674A (hu) |
| EP (1) | EP0214528A3 (hu) |
| JP (1) | JPS6256478A (hu) |
| KR (1) | KR870003097A (hu) |
| AU (1) | AU582271B2 (hu) |
| DD (1) | DD251976A5 (hu) |
| DE (1) | DE3531682A1 (hu) |
| DK (1) | DK423886A (hu) |
| ES (1) | ES2001290A6 (hu) |
| FI (1) | FI863549A (hu) |
| GR (1) | GR862242B (hu) |
| HU (1) | HU195499B (hu) |
| IL (1) | IL79933A0 (hu) |
| NO (1) | NO863539L (hu) |
| NZ (1) | NZ217462A (hu) |
| PT (1) | PT83308B (hu) |
| ZA (1) | ZA866703B (hu) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2206880B (en) * | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
| DE3738980A1 (de) * | 1987-11-17 | 1989-05-24 | Thomae Gmbh Dr K | Mittel zur behandlung von ischaemischen herzerkrankungen |
| EP0330756B1 (de) * | 1987-12-22 | 1996-03-27 | Byk Gulden Lomberg Chemische Fabrik GmbH | Thienotricyclen zur Behandlung von Erkrankungen der Bronchien |
| DE4138909A1 (de) * | 1991-11-27 | 1993-06-03 | Bayer Ag | Aminoalkyl-substituierte 5,6-dihydro-dibenz(b,e)azepin-6,11-dion-11-oxime |
| US5439109A (en) * | 1993-12-28 | 1995-08-08 | Bag-It Products Corp. | Line storage device |
| US6333322B1 (en) * | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| WO2024059085A1 (en) * | 2022-09-12 | 2024-03-21 | Invea Therapeutics, Inc. | Compositions and methods for treatment of inflammatory diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3028001A1 (de) * | 1980-07-24 | 1982-02-18 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue, in 5-stellung substituierte 5,10-dihydro-11h-dibenzo (b,e)(1,4) diazepin-11-one, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel |
| DE3204157A1 (de) * | 1982-02-06 | 1983-08-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte dibenzodiazepinone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| DE3402060A1 (de) * | 1984-01-21 | 1985-08-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3409237A1 (de) * | 1984-03-14 | 1985-09-19 | Dr. Karl Thomae Gmbh, 7950 Biberach | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
-
1985
- 1985-09-05 DE DE19853531682 patent/DE3531682A1/de not_active Withdrawn
-
1986
- 1986-08-19 US US06/898,153 patent/US4668674A/en not_active Expired - Fee Related
- 1986-08-21 EP EP86111580A patent/EP0214528A3/de not_active Withdrawn
- 1986-09-01 GR GR862242A patent/GR862242B/el unknown
- 1986-09-03 FI FI863549A patent/FI863549A/fi not_active IP Right Cessation
- 1986-09-03 IL IL79933A patent/IL79933A0/xx unknown
- 1986-09-04 PT PT83308A patent/PT83308B/pt unknown
- 1986-09-04 DK DK423886A patent/DK423886A/da not_active Application Discontinuation
- 1986-09-04 DD DD86294151A patent/DD251976A5/de unknown
- 1986-09-04 ZA ZA866703A patent/ZA866703B/xx unknown
- 1986-09-04 NZ NZ217462A patent/NZ217462A/xx unknown
- 1986-09-04 JP JP61208831A patent/JPS6256478A/ja active Pending
- 1986-09-04 ES ES8601622A patent/ES2001290A6/es not_active Expired
- 1986-09-04 HU HU863826A patent/HU195499B/hu unknown
- 1986-09-04 NO NO863539A patent/NO863539L/no unknown
- 1986-09-04 KR KR1019860007408A patent/KR870003097A/ko not_active Application Discontinuation
- 1986-09-04 AU AU62341/86A patent/AU582271B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2001290A6 (es) | 1988-05-01 |
| ZA866703B (en) | 1988-05-25 |
| FI863549A0 (fi) | 1986-09-03 |
| AU582271B2 (en) | 1989-03-16 |
| PT83308B (de) | 1988-10-07 |
| US4668674A (en) | 1987-05-26 |
| AU6234186A (en) | 1987-03-12 |
| DD251976A5 (de) | 1987-12-02 |
| DK423886A (da) | 1987-03-06 |
| HUT42472A (en) | 1987-07-28 |
| PT83308A (de) | 1986-10-01 |
| GR862242B (en) | 1987-01-02 |
| KR870003097A (ko) | 1987-04-15 |
| IL79933A0 (en) | 1986-12-31 |
| DE3531682A1 (de) | 1987-03-12 |
| FI863549A (fi) | 1987-03-06 |
| EP0214528A3 (de) | 1987-08-05 |
| HU195499B (en) | 1988-05-30 |
| DK423886D0 (da) | 1986-09-04 |
| JPS6256478A (ja) | 1987-03-12 |
| NZ217462A (en) | 1988-11-29 |
| EP0214528A2 (de) | 1987-03-18 |
| NO863539D0 (no) | 1986-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6882990B2 (ja) | Ｓ−ケタミンの（ｓ）−ｃｓａ塩、ｓ−ケタミンの（ｒ）−ｃｓａ塩、及びｓ−ケタミンの調製プロセス | |
| TWI290927B (en) | 2-Acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine acid-additive salts | |
| CS274420B2 (en) | Method of clock-wise isomer alpha-(4,5,6,7-tetrahydrothieno (3,2-c)-5-pyridyl)-)2-chlorphenyl) methylacetate production | |
| CA2722248C (en) | Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation | |
| EP1467735B1 (en) | Polymorphs of clopidogrel hydrogensulfate | |
| FI80674B (fi) | Foerfarande foer framstaellning av terapeutiskt aktivt (r)-alfa-etyl-2-oxo-1-pyrrolidinacetamid. | |
| US20160060271A1 (en) | Deuterated amlexanox | |
| NO863539L (no) | Fremgangsmaate for isolering av (+)-6-klor-5,10-dihydro-5-((1-metyl-4-piperidinyl)acetyl) -11h-dibenzo (b,e) (1,4) diazepin-11-on. | |
| Dale et al. | The synthesis and anti-acetylcholinesterase activities of (+)-physostigmine and (+)-physovenine | |
| HU228458B1 (en) | Duloxetine salts for producing pharmaceutical compositions | |
| WO1999054303A1 (fr) | Derives tetrahydrobenzindoles actifs au plan optique | |
| NZ229760A (en) | 3-(1-carboxymethyl-2-carboxypyrrol-4-yl)pentanedioic acid and the distrontium salt thereof as a pharmaceutical compound | |
| WO2023076533A1 (en) | Solid forms of mesembrine and therapeutic uses thereof | |
| KR102509190B1 (ko) | 트리메부틴 말레산염의 다형체 및 이의 사용방법 | |
| NO127447B (hu) | ||
| NO154193B (no) | Fremgangsmùte for fremstilling av monohydratisert picotami d | |
| DK170972B1 (da) | (+)-1-[(3,4,5-Trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamin samt lægemidler med indhold af denne forbindelse | |
| NO164596B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinolinderivater. | |
| FI101700B (fi) | Menetelmä terapeuttisesti käyttökelpoisen, optisesti aktiivisen 2-amin o-N-(2,6-dimetyylifenyyli)-N-£3-(3-pyridyyli)-propyyli|propanamidin ha ppoadditiosuolan valmistamiseksi | |
| JPS58148883A (ja) | ピリドベンゾジアゼピノン化合物 | |
| WO2022012587A1 (zh) | 丙烯酮类化合物的丙二酸盐晶型及其制备方法 | |
| ES2359829T3 (es) | Nuevas formas cristalinas de la sal mesilato de 2,3-dimetil-8-(2,6-dimetilbencilamino)-n-hidroxietil-imidazo-[1,2-a]piridin-6-carboxamida. | |
| KR100742134B1 (ko) | 결정성Ｓ-(+)-메틸-2-(2-클로로페닐)-2-(6,7-디히드로티에노[3,2-ｃ]피리딘-5(4Ｈ)-일)아세테이트·캄실레이트를 포함하는약학적 조성물 | |
| RU2644155C1 (ru) | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ | |
| CN116640093A (zh) | 辣椒素-他克林杂化物及其制备方法和应用 |